Masoom Haider, MD, presented “Current Clinical Utility of MRI and Multi-Modality Imaging” virtually during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8th, 2020.
How to cite: Haider, Masoom. “Current Clinical Utility of MRI and Multi-Modality Imaging” October 8th, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/current-clinical-utility-of-mri-and-multi-modality-imaging/
Current Clinical Utility of MRI and Multi-Modality Imaging – Summary:
Masoom Haider, MD, Professor of Medical Imaging at the University of Toronto, discusses the clinical utility of multiparametric MRI (mpMRI) in prostate cancer diagnosis, noting current knowledge and practice gaps and highlighting key areas for future research. He explains that while the benefits of mpMRI in biopsy-naïve men at high risk of prostate cancer have been confirmed several times over and it is increasingly recommended prior to biopsy, mpMRI can still miss between 3 and 11% of clinically significant cancers, so some kind of follow-up strategy or safety net is needed. Dr. Haider then discusses the need for a quality assurance system, like PI-QUAL, to ensure that mpMRIs are correctly performed and interpreted, as well as the need for a directed pathway to create a better flow of patients from initial assessment through to follow-up. He also briefly summarizes research on the comparative risks of lesions visible on mpMRI to lesions invisible on mpMRI, reducing mpMRI through better risk stratification, and comparing cancer detection with mpMRI to cancer detection with 68Ga-PSMA PET/CT. He concludes that a great deal remains to be learned both about the long term implications of using mpMRI and about the best ways to use it.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. Dr. Haider presented this on the second day of the conference. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Masoom Haider, MD, is a Professor of Medical Imaging at the University of Toronto in Ontario. He received his MD from the University of Ottawa and undertook additional training at the University of Toronto and the Cleveland Clinic Foundation. Dr. Haider focuses on prostate cancer localization with MRI using multiparametric approaches; radiologic pathologic correlation in prostate cancer, GU malignancies, and other abdominal and pelvic malignancies; and feature analysis of tumors for imaging biomarker validation and therapy response assessment. He has worked on establishing guidelines for the use of mpMRI for prostate cancer, including the PI-RADS standard for performance and interpretation of prostate mpMRI. Dr. Haider holds three patents on medical imaging technologies and has over 180 publications in peer-reviewed journals.
